

PainChek Delivers Compelling Clinical and Economic Benefits to Aged Care Providers in Scottish Care Trial

Highlights:

- As part of PainChek's continued commercial push into the UK market, the PainChek Adult App was trialled in the Scottish care system in a government funded pilot
- Independent evaluation has confirmed outstanding clinical benefits in utilising the PainChek app, including:
 - up to 40% reduction in falls
 - up to 27% reduction in dependency and care needs
 - significant improvements in clinical outcomes such as a 25% reduction in analgesic usage and a 33% reduction in antipsychotic prescriptions
- It also projected a significant economic benefit – a potential £66 million (~A\$134 million) saving in the Scottish healthcare system across 23,000 residents – delivering an estimated 10:1 return on investment for the Scottish healthcare system
- PainChek is already rapidly growing in the UK with commercial licences covering more than 42,000 aged care beds across 1,000+ care homes – well placed to commercially capitalise on this compelling data
- Successful completion of the InterSystems integration trial enables seamless deployment across electronic care record platforms, unlocking further growth opportunities in the global hospital market

Sydney, Australia, 17 September 2025 – PainChek Ltd (ASX: PCK) ("PainChek" or "the Company"), developer of the world's first smart device-based pain assessment and monitoring application, is pleased to provide a business update on its continued market expansion and commercial push into the UK via recent market testing.

In the UK, PainChek's expansion continues to gather momentum, following the successful completion of the Scottish Care Inspectorate pilot and the InterSystems integration and implementation pilot at Edinburgh Royal Infirmary.

Scottish Care Inspectorate pilot

The Scottish Government-funded pilot, independently evaluated by Edinburgh Napier University in collaboration with the Scottish Care Inspectorate, demonstrated substantial clinical and economic benefits for aged care providers using the PainChek Adult App.

Clinical outcomes

- Positive changes in prescriptions, notably:
 - o 25% less analgesia
 - o 34% reduction in laxatives
 - o 21% reduction in antidepressants
- Improvements in quality of life indicators for residents, such as:
 - o 40% fewer falls, less distress
 - o 47% increase in BMI scores supported less malnutrition
 - o 27% decrease in dependency
- High workforce perception with a large majority of staff believing it to be an effective digital solution to pain management
- PainChek aligns with the national strategy of Scotland for improving dementia pain management, addressing clinical and ethical concerns

Read the full report via this link: <https://www.dhi-scotland.com/resources/evaluation-of-a-digital-solution-for-the-assessment-and-management-of-pain>

Renaissance Care is PainChek's largest client in Scotland and were part of the trial. It operates 18 care homes across Scotland, caring for around 750 people, and initially trialled PainChek through the Scottish Care Inspectorate pilot funded by the Government to evaluate the impact it has on the operations and outcomes for its residents. Following this successful pilot, Renaissance Care rolled PainChek out across all of its services and have reported immense benefit.

Residents are now receiving better care as a result, and medications are being regularly reviewed and optimised with healthcare professionals. The impact on the residents mean they are more engaged in meaningful activity, showing fewer instances of stress.

"We are now seeing some care homes getting 5's & 6's in their inspections from the regulator because of the pain assessments and the residents overall wellbeing" – Lauren Kenny Clinical Quality Manager at Renaissance Care

Analysis of Healthcare Economics

Analysis of a Scottish Care Inspectorate model using validated healthcare costing data has now been completed, showing the realised economic benefits of incorporating PainChek into Scotland's aged care sector as a state-of-the-art pain management process.

The analysis **estimates a ~£66 million cash-releasing benefit for Scotland Health based on implementing PainChek across 60% of Scottish care homes (representing approximately 23,000**

residents) over five years, delivering an estimated 10:1 return on investment for the Scottish healthcare system.

These clinical and economic results are now under review by the Scottish government as validation and support for expanding PainChek across Scotland's 38,000 aged care beds.

The evaluation of this project marks a significant step in the impact PainChek is able to deliver in supporting national strategies for pain management in dementia. These clinical and economic outcomes will have positive impact within the UK and overseas.

InterSystems – Edinburgh Royal pilot study

InterSystems is a global provider of advanced data management, integration, and analytics solutions for complex, data-intensive industries within healthcare, delivering software and services like HealthShare and TrakCare for Electronic Health Records (EHRs), care planning, and population health management. Headquartered in Boston, Massachusetts, USA, the company has business presence across the Americas, Europe, Africa, Middle East, and Asia-Pacific.

The PainChek integration with InterSystems and the implementation phase pilot at Edinburgh Royal Infirmary in Scotland has now been successfully concluded by the Specialist Pain Nurse team. The integration enables PainChek to integrate seamlessly with the InterSystems TrakCare electronic care record platforms, which are established across hospitals globally. Moreover, the pilot study has validated the use of PainChek within the hospital sector, saving significant time in documentation and improving communication between healthcare professionals working in the hospital. The pilot study is now moving into phase two to assess the use of PainChek within specific hospital wards, for use by both Nurses and Healthcare teams. This milestone positions the Company to accelerate deployment across the InterSystems global hospital network.

PainChek CEO Philip Daffas commented:

"There are two key drivers to achieve government funding for new medical products, improving patient health and reducing healthcare costs. The Scottish Care Inspectorate pilot has demonstrated that embedding PainChek into the aged care environment can achieve both. These outcomes data have significant value for PainChek's expansion into the UK market and overseas. We also welcome the positive conclusion of the hospital pilot in Edinburgh and the global hospital market opportunities that can be leveraged with the InterSystems integration project."

PainChek is advanced in a number of new licence and global partnership opportunities and looks forward to updating the market in due course as further licences are secured.

The Company is unable to provide an estimate for the additional revenue to be derived from these initiatives. The actual revenues will be disclosed in future quarterly cash flow reports.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,900 aged care facilities, with more than 12,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>